Latorre Julius Gene S, Chou Sherry Hsiang-Yi, Nogueira Raul Gomes, Singhal Aneesh B, Carter Bob S, Ogilvy Christopher S, Rordorf Guy A
Department of Neurology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
Stroke. 2009 May;40(5):1644-52. doi: 10.1161/STROKEAHA.108.535534. Epub 2009 Mar 12.
Hyperglycemia strongly predicts poor outcome in patients with aneurysmal subarachnoid hemorrhage, but the effect of hyperglycemia management on outcome is unclear. We studied the impact of glycemic control on outcome of patients with aneurysmal subarachnoid hemorrhage.
A prospective intensive care unit database was used to identify 332 patients with hyperglycemic aneurysmal subarachnoid hemorrhage admitted between January 2000 and December 2006. Patients treated with an aggressive hyperglycemia management (AHM) protocol after 2003 (N=166) were compared with 166 patients treated using a standard hyperglycemia management before 2003. Within the AHM group, outcome was compared between patients who achieved good (mean glucose burden <1.1 mmol/L) and poor (mean glucose burden >or=1.1 mmol/L) glycemic control. Poor outcome was defined as modified Rankin scale >or=4 at 3 to 6 months. Multivariable logistic regression models correcting for temporal trend were used to quantify the effect of AHM on poor outcome.
Poor outcome in AHM-treated patients was lower (28.31% versus 40.36%) but was not statistically significant after correcting for temporal trend. However, good glycemic control significantly reduced the incidence of poor outcome (OR, 0.25; 95% CI, 0.08 to 0.80; P=0.02) compared with patients with poor glycemic control within the AHM group. No difference in the rate of clinical vasospasm or the development of delayed ischemic neurological deficit was seen before and after AHM protocol implementation.
AHM results in good glucose control and significantly reduces the odds for poor outcome after aneurysmal subarachnoid hemorrhage in glucose-controlled patients. Further studies are needed to confirm these results.
高血糖强烈预示着动脉瘤性蛛网膜下腔出血患者的预后不良,但高血糖管理对预后的影响尚不清楚。我们研究了血糖控制对动脉瘤性蛛网膜下腔出血患者预后的影响。
使用前瞻性重症监护病房数据库,确定2000年1月至2006年12月期间收治的332例高血糖动脉瘤性蛛网膜下腔出血患者。将2003年后采用积极高血糖管理(AHM)方案治疗的患者(N = 166)与2003年前采用标准高血糖管理治疗的166例患者进行比较。在AHM组中,比较血糖控制良好(平均血糖负荷<1.1 mmol/L)和不佳(平均血糖负荷≥1.1 mmol/L)的患者的预后。不良预后定义为3至6个月时改良Rankin量表≥4。使用校正时间趋势的多变量逻辑回归模型来量化AHM对不良预后的影响。
AHM治疗患者的不良预后较低(28.31%对40.36%),但在校正时间趋势后无统计学意义。然而,与AHM组中血糖控制不佳的患者相比,良好的血糖控制显著降低了不良预后的发生率(OR,0.25;95%CI,0.08至0.80;P = 0.02)。AHM方案实施前后,临床血管痉挛发生率或迟发性缺血性神经功能缺损的发生情况无差异。
AHM可实现良好的血糖控制,并显著降低血糖控制患者动脉瘤性蛛网膜下腔出血后不良预后的几率。需要进一步研究来证实这些结果。